Integrating Modified-Release Systems with Personalized Medicine:

A Salient Framework for Disease Management

Pranab Moudgil¹, Sangita Mishra¹, Lekha S¹, Vinni Kalra², M P Venkatesh^1,3*

¹Centre of Excellence in Regulatory Sciences, Dept. of Pharmaceutics, JSS College of Pharmacy, JSSAHER, Mysuru 570015, Karnataka, India.

²Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala 147002, Punjab, India.

³Faculty of Pharmaceutical Sciences, UCSI University, Malaysia.

*Corresponding Author E-mail: venkateshmpv@jssuni.edu.in

ABSTRACT:

Modified-release (MR) drug delivery systems offer precise spatiotemporal control of drug exposure, allowing for alignment with interindividual pharmacokinetic (PK) and pharmacodynamic (PD) variability, and addressing the fundamental shortcomings of conventional fixed-dose therapies in chronic disease management. This narrative review critically examines recent advances in MR platforms, including stimuli-responsive systems and advanced nanocarriers that enable patient-centric customization based on age, physiological status, genetic variability, and comorbidity profiles. The integration of MR formulation design with quantitative clinical pharmacology tools, such as model-informed precision dosing (MIPD), physiologically based pharmacokinetic (PBPK) modeling, and in vitro–in vivo correlation (IVIVC), is highlighted as a key strategy for enhancing translational predictability, optimizing therapeutic performance, and facilitating regulatory acceptance. Emerging manufacturing technologies, particularly three-dimensional (3D) printing, are discussed as disruptive enablers of on-demand, patient-specific MR dosage forms, with growing evidence of clinical and operational feasibility in pediatric populations and complex treatment regimens. Furthermore, the convergence of digital patient twins (DPTs), real-time clinical data streams, and adaptive analytics is positioned as a transformative paradigm for dynamically optimized therapies. Collectively, these developments establish an integrated framework for MR-enabled personalized medicine, supporting the rational design and scalable implementation of individualized therapeutic strategies for chronic diseases requiring long-term pharmacological intervention.

KEYWORDS: Modified-release formulations, Personalized Medicine, 3D printing, Digital Patient Twins, Model-Informed Precision Dosing.

1. INTRODUCTION:

Current clinical therapies face critical challenges in achieving consistent therapeutic outcomes across diverse patient populations with varied therapeutic needs. This variation in drug response among different individuals is caused by various factors such as genetic polymorphisms, physiological differences, environmental factors, and state or manifestation of the underlying diseases. These factors collectively undermine the effectiveness of standardized principles in drug development and clinical administration, which have been the foundation of clinical research. Conventional immediate-release (IR) formulations have been proven to be effective for many patients, but these fail to efficiently account for and address the substantial heterogeneity in absorption, distribution, metabolism, and excretion (ADME) profiles that characterize real-world patient populations^1–6. To overcome these limitations, Modified-release (MR) formulations can be considered. Such formulations provides several benefits like controlled/prolonged drug release, site-specific drug delivery, reduce dose dumping, improved patient compliance etc.. These properties help to regulate drug concentrations, reduce dose related side effects and efficiently manage treatment.

Personalized medicine (PM) represents a significant shift in clinical development from standardized therapies to a more real-world data and physiology-driven therapeutic approach⁷. It integrates genomic, phenotypic, and clinical information to optimize effective treatment, catering to the unique disease and physiological characteristics of patients even within the same disease class. The adoption of MR technology in the development of PM would create novel and effective opportunities to customize drug delivery with patient-specific therapeutic needs, thereby advancing the development of precision therapies^8–10. In this study, a framework for the development of MR-based PMs has been proposed that provides visual guidance to drive drug development and innovation in this therapeutic type.

2. METHODS:

A structured study selection and synthesis method was adopted to align with the article’s narrative review with selective quantitative elements.

2.1 Data Sources and Search Strategy:

Primary sources included peer‑reviewed articles, regulatory guidance, and online expert reviews relevant to MR technologies, personalized medicines, digital twins, and advances in therapeutic development retrieved from published articles and available official regulatory sources including FDA, EMA, ICH, etc..

3. DISCUSSION:

3.1 MR Formulations:

MR formulations are engineered drug delivery systems designed to control the rate, timing and location of drug release to achieve specific PK objectives that may be unattainable using conventional IR dosage forms^11-13. These systems encompass extended-release (providing sustained drug delivery over prolonged periods), delayed-release (targeting specific gastrointestinal sites), and controlled-release mechanisms (maintaining predetermined plasma concentrations)^14-16.

According to a report on the market potential of MR formulations by Future Market Insights, the global MR formulations market is forecasted to grow from USD 282.1 billion in 2025 to USD 524.7 billion by 2035. The insights data are illustrated in Table 1. This is a definite indication that the pharmaceutical industry is acknowledging the revolutionary therapeutic potential of MR formulations.

Table 1: Global modified-release formulations market forecast, 2025–2035

Parameter	Value / Description
Global market size (2025)	USD 282.1 billion
Projected market size (2035)	USD 524.7 billion
CAGR (2025–2035)	6.4%
Dominant release mechanism (2025)	Extended-release (ER) (41.2% share)
Leading formulation type (2025)	Matrix tablets (29.0% of MR formulations)
Key drivers	Chronic disease burden, need for improved adherence, and regulatory support for MR

3.2 Paradigm of Personalized Medicines:

3.2.1 Genomic, Phenotypic, and Clinical Stratification Approaches: Patient stratification based on molecular, genetic, and clinical characteristics to optimize therapeutic selection and dosing facilitates the development of PMs. These stratification techniques play vital role in identifying appropriate drug targets, treatment regimens, and pharmacogenomic variations. Table 2 summarizes genomic, phenotypic, and clinical stratification approaches.

Table 2: Patient stratification approaches in personalized medicine development

Stratification Type	Methods/Approaches	Key Findings/Insights	Examples of Application
Genomic Stratification	· Next-generation sequencing (NGS) · Whole-genome sequencing (WGS) ^1,18,19	· Identifies genetic variants affecting drug metabolism · ~99% of genetic variants are rare Single Nucleotide Polymorphisms (SNPs) · SNPs account for 20–40% variation in drug responses^2,7,20	Pharmacogenomic profiling of ADME genes reveals polymorphisms in drug-metabolizing enzymes and transporters that influence PK parameters^9,21,22
Phenotypic Stratification	· Biomarker analysis · Disease subtype characterization · Functional assessments^1,4,8	Identifies patient subgroups likely to respond to specific therapies	UGT1A1*28 genotyping for irinotecan dose reduction in colorectal cancer to assess tolerance to treatment^23
Clinical Stratification	· Demographic factors (age, sex, body weight), Comorbidities · Concomitant medications · Renal and hepatic function · Lifestyle factors^20,21	· Guides treatment development protocols · Ensures dosing adjustments based on patient-specific clinical conditions^21,24	Metformin dose reduction in elderly Chronic Kidney Disease (CKD) patients with eGFR < 45 mL/min^25

3.2.2 Variability in ADME Processes:

Inter-patient variability in ADME processes represents a critical determinant of the therapeutic outcomes and safety profiles of drugs. Variability in absorption rates is due to differences in gastrointestinal physiology, drug solubility and permeability characteristics, formulation design, food-drug interactions, and transporter expression^6,15. Drug distribution in the patient’s body is influenced by plasma protein binding, tissue perfusion, body composition, and physiological barriers^26,27.

Metabolism exhibits the greatest inter-individual variability, with genetic polymorphisms in cytochrome P450 enzymes (particularly CYP2D6, CYP2C9, CYP2C19, and CYP3A4) producing phenotypes ranging from poor metabolizers to ultra-rapid metabolizers^2–5. With aging, the renal functions such as glomerular filtration rate and tubular secretion capacity suffer a decline which effects the rate of drug clearance significantly. Hence, in such cases use of patient specific dosage form/regimen becomes essential^28-31.

3.2.3 Therapeutic Window and Individual PK/PD Differences:

The therapeutic window varies substantially among patients due to PK/PD heterogeneity across populations. Drugs that have narrow therapeutic window often require precise dosing to avoid toxicity effects^32,33. Advances in Model-informed precision dosing (MIPD) provide quantitative frameworks for developing individualized dosing using PK modeling. This can account for inter-individual variability, address patient-specific clinical needs, and reduce the potential toxic effects of drugs^34,35.

3.3 Scope of MRDFs for PM development:

3.3.1 Drug Release Rate aligned with Patient-Specific Therapeutic Requirements:

The fusion of MR technology and PM has the ability to align drug release profiles with the PK-PD characteristics of individual patients^36,37. Nowadays, 3D printing technologies have emerged as transformative tools for the design and development of patient-specific MR formulations. These are characterized by drug release profiles, physiology-specific dosage strengths, and multi-therapeutic combinations^38,39. Furthermore, state-of-the art techniques such as semi-solid extrusion, fused deposition modeling, and binder jetting have facilitated on-demand manufacturing of personalized dosage therapeutic forms in both hospital and community pharmacy settings^40-43. Table 3 outlines the advances in MR technology that are enabling the development of patient-specific drug release profiles along with current limitations in clinical adoption.

Table 3: Scope of MR technology for development of PM

Aspect	Description	Examples /Key Aspects
MR–PM synergy	MR technology can align drug release profiles with patient specific PK–PD profile, to enable tailored exposure and improved safety/efficacy.	Enables dose and release kinetics to be matched to age, organ function, genotype, and comorbidity.
3D printing for personalized MR	Facilitates on-demand manufacturing of patient-specific MR formulations with: · Customized release profiles · Physiology‑specific dose strengths · Multi‑therapeutic combinations (polypills)	· Techniques: semi‑solid extrusion, fused deposition modeling (FDM), binder jetting · Settings: hospital and community pharmacy
Advanced biodegradable polymer systems	Physiology‑specific polymers engineering to attain stimuli‑responsive release.	Stimuli: pH, temperature, enzymatic activity, disease‑specific biomarkers^44.45 Benefits: targeted delivery, optimized local concentration, reduced systemic toxicity^46,47
Current limitations in clinical adoption	· Sequential use of MR formulations and separate pharmacogenomic testing · Post‑approval dose adjustment studies to refine regimens	Example: HLA‑B*1502 screening for carbamazepine to mitigate the risk of Stevens‑Johnson syndrome is required, but no MR product yet integrates this marker to adjust release kinetics^48,49 Example: Dosage adjustment of citalopram in patients with CYP2C19 poor metabolizers which resulted in lower efficacy and tolerability^50

3.4 Role of MRDFs in Individualized Therapy:

3.4.1 Tailored Drug Exposure Profiles as per Patient Physiology and Disease Characteristics:

MR formulations have the ability to tailor drug exposure profiles as per patient-specific ADME characteristics^51,52. Population-specific PK approaches identify covariates explaining variability among patients and enable the development of covariate-adjusted dosing algorithms incorporated into MR products^53,54.

3.4.2 Influence of Age, Metabolic Capacity, Comorbidities, and Drug Tolerance: A patient’s age profoundly influences the performance of MR formulations through multiple mechanisms. It is found that pediatric populations exhibit immature drug-metabolizing enzyme systems, altered gastrointestinal physiology, and body composition differences. These obstacles necessitates the use of flexible dosage forms that include mini-tablets, pellets, and microparticles, and reduced dosing intervals, which will improve compliance, convenience and adherence to treatment regimens to allow pharmacometrics studies dosing capabilities⁵⁵. Technological advances like hospital-based 3D printing have enabled production of personalized pediatric MR formulations addressing PK challenges and narrow therapeutic windows^40,56.

A patient’s physiological tolerance to the drug and treatment history also influences optimal MRDFs characteristics. Moreover, any prior exposure to drugs and responses can alter receptor sensitivity, metabolic enzyme expression, and physiological responses to a new treatment. Currently, Precision Cohort Treatment Option (PCTO) leverages Electronic Health Record (EHR) data to design and execute personalized treatment regimens based on clinical outcomes in similar patient cohorts. This enables data-driven development of personalized regimens without the need for prospective trials^31,57,58.

3.4.3 Reduced Dosing Frequency and Stabilized Plasma Levels to improve treatment adherence: Patients on therapies based on ER formulations have been found to demonstrate superior adherence compared to those on treatments with IR products across multiple chronic disease medications. A comprehensive study of 15 chronic medications demonstrated that ER therapy users achieved adjusted medication possession ratios of 80.2% versus 74.8% for IR users (difference 5.4%, p<0.01). The benefits acquired through improved adherence were found to have sustained for over two years. This magnitude of improvement in treatment adherence significantly translates to clinically meaningful outcomes. It is found that medicines like metoprolol succinate extended-release (Toprol XL®) and isosorbide mononitrate extended-release (Imdur®) have resulted in a reduction of major cardiovascular events following myocardial infarction^13-15,56,59.

3.5 Technological approaches to enable personalization in MR formulations:

MR technologies utilize both conventional and innovative platforms to deliver controlled drug release and profiles as per unique patient and disease characteristics. For instance, hydrophilic matrix systems, utilize polymers such as hydroxypropyl methylcellulose (HPMC) to produce matrices that swell after getting in contact with gastrointestinal fluids, thus drug release is controlled through erosion and diffusion. The matrices allow the drug delivery to be sustained and thus the delivery is adaptable to individual gastrointestinal transit times⁶⁰.

3.6 PK/PD Considerations in Personalized MR Therapy:

Model-informed precision dosing (MIPD), physiologically based pharmacokinetic (PBPK) models, and in vitro–in vivo correlation (IVIVC) models leverage clinical covariates of every patient, take into consideration an individual’s physiological parameters, and simulate patient-specific release profiles and dissolution–absorption linkages. All of these help in developing individually optimized MR therapies^61-64. An example of a Model-informed drug development (MIDD) approach to optimize clinical trial design in new drug development is “Exposure-matching with popPK or PBPK modeling” in pediatric patients to identify appropriate dosing strengths for assessing clinical safety and efficacy in clinical trials⁶⁵. In terms of regulatory decision-making, there are a few MIDD approaches one of which is the “PBPK modeling in combination with pharmacodynamics evaluation” that is being used to assess a compound’s effectiveness and is being used to assess the optimized dosing regimens of hydroxychloroquine (HCQ) for the treatment of SARS-CoV-2⁵⁵.

3.7 Regulatory and developmental perspectives for personalized MR:

Regulatory standards are required to confirm consistent product performance for therapies that are produced outside the traditional manufacturing methods and settings. Regulatory oversight is evolving to promote the adoption and usage of novel manufacturing techniques. There are targeted guidance documents, such as the FDA’s framework on additive manufacturing and the EMA’s Quality-by-Design principles for advanced therapies. Such guidelines lay down detailed steps and set guidance on the implementation of risk-based inspection programs for decentralized production along with greater harmonization in terms of adopting standardized GMP control and validation across these manufacturing modalities6^7,67. All of these can ensure the safety and efficacy of innovative techniques and advance the development of personalized MR formulations^68,69.

4 FUTURE DIRECTIONS:

4.1 Digital twins and real-time pharmacotherapy feedback loops:

Digital patient twins (DPTs) represent a revolutionary shift in the development of personalized MR formulations. They enable drug PK/PD simulations in a digital environment, allowing for iterative adjustments and optimization before clinical administration. The obtained clinical data can be used to estimate clinical efficacy and side effects more accurately⁷⁰. The Swedish Digital Twin Consortium is looking at the ways of building patient-specific digital twins to produce the virtual copies based on the anatomical and physiological characteristics of patients. The customized drug regimens are then administered multiple times to identify the most effective therapies and doses prior to their actual use and administration in clinical trials^28,71,72.

Therapeutic feedback loops continuously incorporate real-time health monitoring data from different sources like wearable devices, implantable sensors, and point-of-care diagnostics. This can facilitate dynamic adjustment of formulations as per incoming clinical data^7,10. Presently, two-way data exchange between patients and their digital twins has been implemented in only 11% of “claimed digital twin” systems⁷³. Ongoing refinement and continuous improvement of data management and analytics-driven drug development can revolutionize the treatment of chronic diseases, resulting in long-term therapeutic benefits^46,74.

4.2 Dynamic and Biodegradable Polymer Systems Tuned to Patient Physiology:

Advanced biodegradable polymer systems enable the creation of critical innovation pathways for patient-centric MR formulations. Natural polymers (chitosan) and synthetic polymers (polylactic acid) offer customizable dissolution kinetics that can match with individual patients’ metabolic profiles²¹. “Smart polymers" that are stimulus-responsive cater to patient-specific physiological parameters such as pH gradients, temperature variations, enzymatic activity, inflammation biomarkers, etc.. These enable adaptive drug release aligned with specific states of disease. Crosslinking techniques, nanotechnology integration, and microencapsulation platforms provide additional tools to optimize drug release profiles. The integration of biodegradable polymer systems with MR formulations offers benefits including enhanced drug stability, extended presence in target tissues, improved bioavailability (BA), reduced dosing frequency, and site-specific delivery to targeted anatomical sites^44,75.

4.3 Personalized pharmacist-led compounding and decentralized manufacturing:

Hospital-based and community pharmacy platforms are allowing on-demand production of patient-specific MR formulations with precise dosing, customized release profiles, and multi-drug combination therapies^26,76.

Automated compounding systems integrating robotics, smart manufacturing systems, digital batch records, and inline quality control enable standardized production of personalized dosage forms meeting regulatory requirements.

The CurifyLabs compounding system solution demonstrated feasibility of personalized pediatric MR formulation production in hospital pharmacy settings has shown higher acceptability and efficiency, with significant reductions in pharmacist time requirements (55% decrease) and improved mass uniformity compared to manual compounding. Semi-automated platforms produced 200 multi-drug capsules in 45 minutes, with further efficiency gains anticipated through pre-manufactured pharmaceutical inks and integrated quality systems^40-42.

A few of the approved formulations include personalized isoleucine tablets for maple syrup urine disease (MSUD), subdivided spironolactone tablets for pediatric dosing, and warfarin formulations with dose titration capabilities that have been produced as per guidelines laid down in various pharmacopeias^9,26,43,74.

4.4 MR formulations in precision pharmacotherapy for chronic disease management:

The amalgamation of novel MR formulations, digital health platforms, pharmacogenomic studies, and advanced manufacturing capabilities has projected MR formulations as critical elements of precision pharmacotherapy for chronic diseases^7,11. Critical chronic conditions require lifelong medication regimens, optimized dosing, strict adherence protocols, and personalization that directly impacts morbidity and mortality by improving the precision of therapeutic effectiveness³³.

PM development approaches integrate genetic testing, therapeutic drug monitoring, digital health monitoring, and precision cohort analyses. All of these are transforming chronic disease pharmacotherapy from empirical to evidence-based science supported by data-driven insights to continuously improve the quality and effectiveness of these therapies.

5. CONCLUSION:

MR formulations are advancing the development of PMs to directly address physiological and disease variability among diverse patient populations. These are achieved by matching controlled-release profiles to individual PK/PD characteristics of patients. Clinical development of PMs is supported by PBPK, MIPD, IVIVC, and advanced technologies like 3D printing, decentralized compounding etc. The emerging technologies such as DPTs, real-time monitoring, stimulus‑responsive polymers, and AI‑guided drug design have set the stage for the development of state-of-the-art precision therapies. Considerable effectiveness has been observed through early feasibility studies, particularly in pediatric patients where managing drugs with narrow therapeutic indices has shown promising clinical outcomes. However, fully realizing the therapeutic potential of MRs requires a coordinated approach across multiple domains. These include improved regulatory pathways for bioequivalence and quality assessment, novel reimbursement strategies for payers aligned with technological innovation, comprehensive pharmacogenomic testing and therapeutic drug monitoring infrastructure in healthcare systems, and effective public health systems to ensure equitable access and clinical data protection. The integration of pharmacogenomics, therapeutic drug monitoring, and real-time digital health data, potentially enabled by digital patient twins, will be essential for optimizing adaptive therapy. Coordinated regulatory innovation and cross-sector collaboration are critical to establish MR platforms as a foundation for precision therapeutics in chronic and lifelong disease management.

6. REFERENCES:

1. Swapnaa B, Kumar SV. Personalized medicine-A novel approach in cancer therapy. Research Journal of Pharmacy and Technology. 2017; 10(1): 341. doi: 10.5958/0974-360X.2017.00069.5

2. Rahul Khiste, Nilkanth Bhapkar, Nilesh Kulkarni. A Review on Applications of Hydroxy Propyl Methyl Cellulose and Natural polymers for the development of modified release drug delivery systems. Research Journal of Pharmacy and Technology. 2021; 14(2): 1163-1170. doi: 10.5958/0974-360X.2021.00208.0

3. Darwich AS, Ogungbenr K, Hatley OJ, Rostami-Hodjegan A. Role of pharmacokinetic modeling and simulation in precision dosing of anticancer drugs. Transl Cancer Res. 2017 Dec; 6(S10): S1512–29

4. Romley JA, Xie Z, Chiou T, Goldman D, Peters AL. Extended-release formulation and medication adherence. Journal of General Internal Medicine. 2020 Jan; 35(1): 354-6. doi: 10.1007/s11606-019-05275-1

5. Djuris J, Cvijic S, Djekic L. Model-informed drug development: in silico assessment of drug bioperformance following oral and percutaneous administration. Pharmaceuticals. 2024 Jan 30; 17(2): 177. doi: 10.3390/ph17020177

6. Grzegorzewski J, Brandhorst J, Green K, Eleftheriadou D, Duport Y, Barthorscht F, Köller A, Ke DY, De Angelis S, König M. PK-DB: pharmacokinetics database for individualized and stratified computational modeling. Nucleic Acids Research. 2021 Jan 8; 49(D1): D1358-64. doi: 10.1093/nar/gkaa990

7. Fischer RP, Volpert A, Antonino P, Ahrens TD. Digital patient twins for personalized therapeutics and pharmaceutical manufacturing. Frontiers in Digital Health. 2024 Jan 5; 5: 1302338. doi: 10.3389/fdgth.2023.1302338

8. Bachhav R, Bachhav P, Deore R, Sonawane G, Surana K, Mahajan S. Biodegradable Polymers in Drug Delivery: A Detailed Review. Asian Journal of Pharmaceutical Research. 2025 May 5; 153–8. doi: 10.52711/2231-5691.2025.00025

9. Mankar SD, Kale C, Kanchan J. 3D printing technology-A computer aided Design-A review. Research Journal of Science and Technology. 2019 Jul 1; 11(3): 217-24. doi: 10.5958/2349-2988.2019.00032.9

10. Hemanth KG, Hemamanjushree S, Abhinaya N, Pai R, Girish KP. 3D printing: A review on technology, role in novel dosage forms and regulatory perspective. Research Journal of Pharmacy and Technology. 2021; 14(1): 562-72. doi: 10.5958/0974-360X.2021.00102.5

11. Marques L, Costa B, Pereira M, Silva A, Santos J, Saldanha L, Silva I, Magalhães P, Schmidt S, Vale N. Advancing precision medicine: a review of innovative in silico approaches for drug development, clinical pharmacology and personalized healthcare. Pharmaceutics. 2024 Feb 27; 16(3): 332. doi: 10.3390/ pharmaceutics16030332

12. Patel R, Patel A. In vivo–In Vitro correlation (IVIVC) in drug development: bridging preclinical and clinical outcomes for regulatory approvals. World Journal of Advanced Research and Reviews. 2024 May 30; 22(2): 2311-28. doi: 10.30574/ wjarr.2024.22.2.1197

13. Mukherjee S, Joshi V, Reddy KP, Singh N, Das P, Datta P. Biopharmaceutical and pharmacokinetic attributes to drive nanoformulations of small molecule tyrosine kinase inhibitors. Asian Journal of Pharmaceutical Sciences. 2024 Dec 1; 19(6): 100980. doi: 10.1016/j.ajps.2024.100980

14. Da Rocha JE, Othman H, Botha G, Cottino L, Twesigomwe D, Ahmed S, Drögemöller BI, Fadlelmola FM, Machanick P, Mbiyavanga M, Panji S. The extent and impact of variation in ADME genes in sub-Saharan African populations. Frontiers in Pharmacology. 2021 Apr 28; 12: 634016. doi: 10.3389/ fphar.2021.634016

15. Yogesh S. Purkar, Rajendra K. Surawase. Overview: A Novel Approach on Extended-Release Tablet. Research Journal of Pharmaceutical Dosage Forms and Technology. 2024; 16(2): 183-8. doi: 10.52711/0975-4377.2024.00029

16. Drummond D, Gonsard A. Definitions and characteristics of patient digital twins being developed for clinical use: scoping review. Journal of Medical Internet Research. 2024 Nov 13; 26: e58504. doi: 10.2196/58504

17. Center for Drug Evaluation and Research. U.S. Food and Drug Administration. 2025. Orange Book Data Files. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files

18. Venkatesh KP, Brito G, Kamel Boulos MN. Health Digital Twins in Life Science and Health Care Innovation. Annu Rev Pharmacol Toxicol. 2024 Jan 23; 64(1): 159–70. doi: 10.1146/annurev-pharmtox-022123-022046

19. Henriksen AP, Rodríguez CL, Currant H, Louloudis I, Biel JH, Herrero-Zazo M, Birney E, Hansen TF, Mazzoni G, Haue AD, Bundgaard H. Genome-wide associations spanning 194 in-hospital drug dosage change phenotypes highlight diverse genetic backgrounds in concurrent drug therapy. Computational and Structural Biotechnology Journal. 2025 Jan 1; 28: 239-48. doi: 10.1016/j.csbj.2025.06.042

20. Maharjan R, Kim NA, Kim KH, Jeong SH. Transformative roles of digital twins from drug discovery to continuous manufacturing: pharmaceutical and biopharmaceutical perspectives. Int J Pharm X. 2025 Dec; 10: 100409. doi: 10.1016/j.ijpx.2025.100409

21. Prajapati SK, Jain A, Jain A, Jain S. Biodegradable polymers and constructs: A novel approach in drug delivery. European Polymer Journal. 2019 Nov 1; 120: 109191. doi: 10.1016/ j.eurpolymj.2019.08.018

22. Sushant M. Ahire, Prerana S. Pawar, Vijayraj N. Sonawane, Shivraj P. Jadhav. Personalized Medicine and Pharmacogenomics: Impact of Genetic variation on Drug Response and Individualized Therapy - A Review. Asian Journal of Pharmacy and Technology. 2026; 16(1): 91-8. doi: 10.52711/2231-5713.2026.00013

23. Dean L. Irinotecan Therapy and UGT1A1 Genotype. 2015 May 27 [Updated 2018 Apr 4]. In: Pratt VM, Scott SA, Pirmohamed M, et al., editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012-, available on https://www.ncbi.nlm.nih.gov/books/NBK294473/

24. Melnyk LA, Oyewumi MO. Integration of 3D printing technology in pharmaceutical compounding: Progress, prospects, and challenges. Annals of 3D Printed Medicine. 2021 Dec 1; 4: 100035. doi: 10.1016/j.stlm.2021.100035

25. Lipska KJ, Bailey CJ, Inzucchi SE. Use of Metformin in the Setting of Mild-to-Moderate Renal Insufficiency. Diabetes Care. 2011 Jun 1; 34(6): 1431–7. doi: 10.2337/dc10-2361

26. Englezos K, Wang L, Tan ECK, Kang L. 3D printing for personalised medicines: implications for policy and practice. Int J Pharm. 2023 Mar; 635: 122785. doi: 10.1016/ j.ijpharm.2023.122785

27. Abd Elaziz M, Al‐qaness MA, Dahou A, Al‐Betar MA, Mohamed MM, El‐Shinawi M, Ali A, Ewees AA. Digital twins in healthcare: Applications, technologies, simulations, and future trends. Wiley Interdisciplinary Reviews: Data Mining and Knowledge Discovery. 2024 Nov; 14(6): e1559. doi: 10.1002/widm.1559

28. Katsoulakis E, Wang Q, Wu H, Shahriyari L, Fletcher R, Liu J, Achenie L, Liu H, Jackson P, Xiao Y, Syeda-Mahmood T. Digital twins for health: a scoping review. NPJ Digital Medicine. 2024 Mar 22; 7(1): 77. doi: 10.1038/s41746-024-01073-0

29. Ferreira R. Understanding Pharmacokinetic Variability: Implications for Therapy. Journal of Pharmacokinetics & Experimental Therapeutics. 2024 Jun 28; 8(3). doi: 10.4172/ jpet.1000248

30. P. V. Kamala Kumari, Y. Srinivasa Rao. Personalized Medicine- A Review. Research Journal of Pharmacy and Technology 2019; 12(8): 3989-3992. doi: 10.5958/0974-360X.2019.00687.5

31. Ng K, Kartoun U, Stavropoulos H, Zambrano JA, Tang PC. Personalized treatment options for chronic diseases using precision cohort analytics. Scientific Reports. 2021 Jan 13; 11(1): 1139. doi: 10.1038/s41598-021-80967-5

32. Minichmayr IK, Dreesen E, Centanni M, Wang Z, Hoffert Y, Friberg LE, Wicha SG. Model-informed precision dosing: state of the art and future perspectives. Advanced Drug Delivery Reviews. 2024 Dec 1; 215: 115421. doi: 10.1016/j.addr.2024.115421

33. Hetvi Pastagia, Anuradha Prajapati, Bhoomi S. Patel, Sachin B. Narkhede, Shailesh Luhar, Sakshi Dineshbhai Tandel. Personalized Medicine: Advancing Precision Medicine used in Autoinflammatory and Related Disorders. Asian Journal of Pharmaceutical Analysis. 2026; 16(1): 34-0. doi: 10.52711/2231-5675.2026.00006

34. Tanaka R. Pharmacokinetic variability and significance of therapeutic drug monitoring for broad-spectrum antimicrobials in critically ill patients. J Pharm Health Care Sci. 2025 Mar 17; 11(1): 21. doi: 10.1186/s40780-025-00425-6

35. Revel J and Gorria P, Modified-Release Formulations: Improving Efficacy and Patient Compliance, Solid Dosage Drug Development and Manufacturing Supplement. 2020 April: s6-s8.

36. Fernandes JB, Teixeira F, Godinho C. Personalized care and treatment compliance in chronic conditions. Journal of Personalized Medicine. 2022 May 1; 12(5): 737. doi: 10.3390/ jpm12050737

37. Zhu B, Zhu Y, Chen D, Jin P. Therapeutic drug monitoring for promotion of rational medication in the elderly: Overview, challenges and opportunities. Precision Medication. 2024 Nov; 1(1): 100006. doi: 10.1016/j.prmedi.2024.10.006

38. Saba Wahid Khan, Indira Parab. A Detailed Review on 3D Bioprinting and it's Application in Pharmaceutical Science. International Journal of Technology. 2023; 13(1): 57-7. doi: 10.52711/2231-3915.2023.00007

39. Akiladevi D, Raman Suresh Kumar, Arunkumar N. A Review on 3D printing Pharmaceutical Manufacturing and applications on Drug Delivery System. Research Journal of Pharmacy and Technology 2019; 12(2): 873-875. doi: 10.5958/0974-360X.2019.00149.5

40. N. Madhavi, A. Nikitha, M. Sreeja, T. Rama Rao. A Review on 3D Printing Technology: Personalized Medicine for Special Population. Research Journal of Pharmaceutical Dosage Forms and Technology. 2025; 17(2): 137-42. doi: 10.52711/0975-4377.2025.00020

41. Chu X, Ye Y, Tang S, Han M, Wang G, Lin S, Sun B, Huang Q, Zhang Y, Chu X, Bao K. Personalized Medication for Chronic Diseases Using Multimodal Data‐Driven Chain‐of‐Decisions. Advanced Science. 2025 Oct; 12(40): e04079. doi: 10.1002/ advs.202504079

42. Yao Y, Zhang L, Chen D, Qin S, Meng M, Guo Q. Global research on the utilization of population pharmacokinetic model: a bibliometric analysis from 2000 to 2024. Frontiers in Pharmacology. 2025 May 12; 16: 1548023. doi: 10.3389/ fphar.2025.1548023

43. Awad A, Goyanes A, Basit AW, Zidan AS, Xu C, Li W, Narayan RJ, Chen RK. A review of state-of-the-art on enabling additive manufacturing processes for precision medicine. Journal of Manufacturing Science and Engineering. 2023 Jan 1; 145(1): 010802. doi: 10.1115/1.4056199

44. Su J, Yang L, Sun Z, Zhan X. Personalized Drug Therapy: Innovative Concept Guided With Proteoformics. Molecular & Cellular Proteomics. 2024 Mar; 23(3): 100737. Doi: 10.1016/j.mcpro.2024.100737

45. Scott K. The Role of Therapeutic Drug Monitoring in Managing Drug Response Variability. Journal of Applied Pharmacy. 2024; 16(3). doi: 10.35248/1920-4159.24.16.427

46. Beaumont C, Young GC, Cavalier T, Young MA. Human absorption, distribution, metabolism and excretion properties of drug molecules: a plethora of approaches. British Journal of Clinical Pharmacology. 2014 Dec; 78(6): 1185-200. doi: 10.1111/bcp.12468

47. Rashmi Shah. Pharmacokinetics: Drug absorption, distribution, metabolism, and excretion (ADME). Pharma Innovation 2019; 8(1): 865-869. doi: 10.22271/tpi.2019.v8.i1n.25492

48. Ferrell PB, McLeod HL. Carbamazepine, HLA-B*1502 and Risk of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: US FDA Recommendations. Pharmacogenomics. 2008 Oct 14; 9(10): 1543–6. doi: 10.2217/14622416.9.10.1543

49. Dean L. Carbamazepine Therapy and HLA Genotype. In: Medical Genetics Summaries. National Center for Biotechnology Information (US), Bethesda (MD); 2012, available on https://europepmc.org/article/nbk/nbk321445#free-full-text

50. Joković D, Milosavljević F, Stojanović Z, Šupić G, Vojvodić D, Uzelac B, Jukić MM, Ćurčin AP. CYP2C19 slow metabolizer phenotype is associated with lower antidepressant efficacy and tolerability. Psychiatry Research. 2022 Jun 1; 312: 114535. doi: 10.1016/j.psychres.2022.114535

51. Díaz-Santiago E, Moya-García AA, Pérez-García J, Yahyaoui R, Orengo C, Pazos F, Perkins JR, Ranea JA. Better understanding the phenotypic effects of drugs through shared targets in genetic disease networks. Frontiers in Pharmacology. 2025 Jan 22; 15: 1470931. doi: 10.3389/fphar.2024.1470931

52. McLachlan AJ, Pont LG. Drug metabolism in older people—a key consideration in achieving optimal outcomes with medicines. Journals of Gerontology Series A: Biomedical Sciences and Medical Sciences. 2012 Feb 1; 67(2): 175-80. doi: 10.1093/gerona/ glr118

53. Mealey KL, Martinez SE, Villarino NF, Court MH. Personalized medicine: going to the dogs?. Human Genetics. 2019 May 1; 138(5): 467-81. doi: 10.1007/s00439-019-02020-w

54. Culliford R, Lawrence SE, Mills C, Tippu Z, Chubb D, Cornish AJ, Browning L, Kinnersley B, Bentham R, Sud A, Pallikonda H. Whole genome sequencing refines stratification and therapy of patients with clear cell renal cell carcinoma. Nature Communications. 2024 Jul 15; 15(1): 5935. doi: 10.1038/s41467-024-49692-1

55. Khan D, Kirby D, Bryson S, Shah M, Mohammed AR. Paediatric specific dosage forms: Patient and formulation considerations. International Journal of Pharmaceutics. 2022 Mar 25; 616: 121501. doi: 10.1016/j.ijpharm.2022.121501

56. Jørgensen AK, Goyanes A, Basit AW. Entering new domains for 3D printing of drug products. Pharm Technol. 2025 Apr; 49(3): 24-7.

57. Mbah Cornelius Abuchi, Isaac Ndukwe Egbe, Nwaume Emeka Joseph, Ikeyi Adachukwu Pauline, Abah Evelyn Ifeoma, et al. (2025) From Infancy to Frailty: Age and Disease-Linked Modulation of Drug Metabolism. J Pharmacol Drug Metab 8: 1-15

58. Vrbanac J, Slauter R. ADME in drug discovery. In A Comprehensive Guide to Toxicology in Nonclinical Drug Development. 2017 Jan 1 (pp. 39-67). Academic Press.

59. Ngcobo NN. Influence of Ageing on the Pharmacodynamics and Pharmacokinetics of Chronically Administered Medicines in Geriatric Patients: A Review. Clinical Pharmacokinetics. 2025 Mar; 64(3): 335-67. doi: 10.1007/s40262-024-01466-0

60. Siepmann J, Peppas NA. Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Advanced Drug Delivery Reviews. 2012 Dec 1; 64: 163-74. doi: 10.1016/j.addr.2012.09.028

61. Food-Effect Bioavailability and Fed Bioequivalence Studies. U.S. Food and Drug Administration. U.S. Department of Health and Human Services; December 2002, available on https://www.fda.gov/files/drugs/published/Food-Effect-Bioavailability-and-Fed-Bioequivalence-Studies.pdf

62. Zhang W, Zhang Q, Cao Z, Zheng L, Hu W. Physiologically Based Pharmacokinetic Modeling in Neonates: Current Status and Future Perspectives. Pharmaceutics. 2023 Dec 12; 15(12): 2765. doi: 10.3390/pharmaceutics15122765

63. Wang Y, Otte A, Park H, Park K. In vitro-in vivo correlation (IVIVC) development for long-acting injectable drug products based on poly(lactide-co-glycolide). Journal of Controlled Release. 2025 Jan; 377: 186–96. doi: 10.1016/j.jconrel.2024.11.021

64. Sirisha S. A review on ivivc in the development of oral drug formulation: Data obtained from past two decades. Research Journal of Pharmaceutical Dosage Forms and Technology. 2020 Jul 1; 12(3): 198-204. doi: 10.5958/0975-4377.2020.00034.8

65. Madabushi R, Seo P, Zhao L, Tegenge M, Zhu H. Role of Model-Informed Drug Development Approaches in the Lifecycle of Drug Development and Regulatory Decision-Making: Madabushi et al. Pharmaceutical Research. 2022 Aug; 39(8): 1669-80. doi: 10.1007/s11095-022-03288-w

66. Technical Considerations for Additive Manufactured Medical Devices. U.S. Food and Drug Administration. 2017, available on https://www.fda.gov/files/medical%20devices/published/Technical-Considerations-for-Additive-Manufactured-Medical-Devices---Guidance-for-Industry-and-Food-and-Drug-Administration-Staff.pdf

67. Guideline on quality of oral modified release products. European Medicines Agency. 2014. p. 1–16, available on https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-quality-oral-modified-release-products_en.pdf

68. Hilmer SN, Gazarian M. Clinical pharmacology in special populations: the extremes of age. Expert Review of Clinical Pharmacology. 2008 Jul 1; 1(4): 467-9. doi: 10.1586/ 17512433.1.4.467

69. Chen ML, Shah VP, Ganes D, Midha KK, Caro J, Nambiar P, Rocci Jr ML, Thombre AG, Abrahamsson B, Conner D, Davit B. Challenges and opportunities in establishing scientific and regulatory standards for assuring therapeutic equivalence of modified release products: workshop summary report. The AAPS Journal. 2010 Sep; 12(3): 371-7. doi: 10.1208/s12248-010-9201-5

70. Jamalinia M, Weiskirchen R. Advances in personalized medicine: Translating genomic insights into targeted therapies for cancer treatment. Annals of Translational Medicine. 2025 Apr 30; 13(2): 18. doi: 10.21037/atm-25-34

71. Grogan S, Preuss CV. Pharmacokinetics. [Updated 2023 Jul 30]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-, available on https://www.ncbi.nlm.nih.gov/ books/NBK557744/

72. Ernstmeyer K, Christman E, editors. Nursing Pharmacology [Internet]. 2nd edition. Eau Claire (WI): Chippewa Valley Technical College; 2023. Chapter 1 Pharmacokinetics & Pharmacodynamics, available on https://www.ncbi.nlm.nih.gov/ books/NBK595006/

73. Drummond D, Gonsard A. Definitions and characteristics of patient digital twins being developed for clinical use: scoping review. Journal of Medical Internet Research. 2024 Nov 13; 26: e58504. doi: 10.2196/58504

74. Viviani R, Berres J, Stingl JC. Phenotypic Models of Drug–Drug‐Gene Interactions Mediated by Cytochrome Drug‐Metabolizing Enzymes. Clinical Pharmacology & Therapeutics. 2024 Sep; 116(3): 592-601. doi: 10.1002/cpt.3188

75. Jadhav NR, Patil A, Karne HU, Soni SL. Advances in Biodegradable Polymer-based Drug Delivery Systems. Journal of Polymer and Composites. 2025; 13(4): 326–38.

76. Jørgensen AK, Griffen J, Wills R, Parhizkar M, Goyanes A, Basit AW. Enabling Personalised 3D Printed Extended-Release Oral Drug Products: Transmission Raman Spectroscopy as a Rapid Quality Control Tool. European Journal of Pharmaceutical Sciences. 2025 Oct 20: 107341. doi: 10.1016/j.ejps.2025.107341

Received on 14.04.2026      Revised on 16.05.2026

Accepted on 13.06.2026   Published on 07.07.2026

Available online from July 10, 2026

Res.  J. Pharma. Dosage Forms and Tech.2026; 18(3):209-216.

DOI: 10.52711/0975-4377.2026.00031

©AandV Publications All Right Reserved

This work is licensed under a Creative Commons Attribution-Non Commercial-Share Alike 4.0 International License. Creative Commons License.